Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physicians Choice (TPC) in Subjects with Hormonal Receptor Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed at Least Two Prior Chemotherapy Regimens
Study of IMMU-132 in HR+/HER2- Metastatic Breast Cancer (TROPICS-02)
Sponsor: Immunomedics, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS3688
U.S. Govt. ID: NCT03901339
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine whether treatment with sacituzumab govitecan could provide a better response and improve survival (the amount of time you live without your cancer growing) than other forms of cancer treatment (either Eribulin, Capecitabine, Gemcitabine, Vinorelbine).
This study is closed
Investigator
Dawn Hershman, MD
Do You Qualify?
Are 18 years of age or older? Yes No
Have you been diagnosed with metastatic breast cancer? Yes No
Have you received at least 2 but no more than 4 prior treatments for metastatic breast cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE